Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatos...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonnekens, Julie, van Kranenburg, Melissa, Beerens, Cecile E.M.T., Suker, Mustafa, Doukas, Michael, van Eijck, Casper H.J., de Jong, Marion, van Gent, Dik C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997239/
https://www.ncbi.nlm.nih.gov/pubmed/27570553
http://dx.doi.org/10.7150/thno.15311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997239/
https://www.ncbi.nlm.nih.gov/pubmed/27570553
http://dx.doi.org/10.7150/thno.15311

Ejemplares similares